Return
DARATUMUMAB MONOTHERAPY VERSUS ACTIVE MONITORING IN PATIENTS WITH HIGH-RISK SMOLDERING MULTIPLE MYELOMA: AQUILA OUTCOMES BASED ON MAYO 2018/IMWG 2020 RISK STRATIFICATION, IMWG 2020 PLUS CYTOGENETIC CRITERIA, AND AGE
S
V
D
C
H
S
L
B
L
B
M
M
G
T
S
M
H
B
U
P
K
M
Y
C
M
M
G
V
R
S
L
R
D
C
R
DOI:.png)
Abstract
En
Journal
IF:
7.9
Papers:
6.4K
Citations:
2.2W

